Table 1.
Baseline clinical and hemodynamic characteristics in patients undergoing TVR/TVr
| Characteristics | All patients (N = 86) | TVR (N = 39) | TVr (N = 47) | P value | Isolated TVR/TVr (N = 34) | Concomitant TVR/TVr (N = 52) | P value |
|---|---|---|---|---|---|---|---|
| Age, years (n = 86) | 64 ± 13 | 63 ± 12 | 64 ± 14 | 0.82 | 66 ± 10 | 62 ± 15 | 0.16 |
| Female, % | 59.3% (51) | 69.3% (27) | 51.1% (24) | 0.08 | 65% (22) | 56% (29) | 0.41 |
| Comorbidities, % (n) | |||||||
| Hypertension | 72% (62) | 64.1% (25) | 78.7% (37) | 0.13 | 62% (21) | 79% (41) | 0.08 |
| Diabetes mellitus | 41.8% (36) | 56.4% (22) | 29.7% (14) | 0.01 | 50% (17) | 36.5% (19) | 0.22 |
| Chronic kidney disease | 48.8% (42) | 51.2% (20) | 46.8% (22) | 0.68 | 52.9% (18) | 46.2% (24) | 0.54 |
| Stage 1 (GFR > 90) | 10% (8) | 12% (4) | 8.5 % (4) | 7.1% (2) | 11.5% (6) | ||
| Stage II (GFR 60-89) | 41% (33) | 36.5% (12) | 44.7% (21) | 50% (14) | 36.5% (19) | ||
| Stage III (GFR 30-59) | 36% (29) | 36.5% (12) | 36.2% (17) | 35.7% (10) | 36.5% (19) | ||
| Stage IV (GFR 15-29) | 6.5% (5) | 6% (2) | 6.4% (3) | 3.6 % (1) | 7.7% (4) | ||
| Stage V (GFR < 15) | 6.5% (5) | 9% (3) | 4.3% (2) | 3.6% (1) | 7.7% (4) | ||
| COPD | 22.1% (19) | 25.6% (10) | 19.2% (9) | 0.47 | 32.4% (11) | 15.4% (8) | 0.06 |
| Atrial fibrillation | 88.3% (76) | 89.7% (35) | 87.2% (41) | 0.72 | 82.4% (28) | 92.3% (48) | 0.16 |
| MELD score (n = 33) | 12 ± 7 | 13 ± 7 | 12 ± 6 | 0.72 | 12 ± 8 | 12 ± 6 | 0.92 |
| Hemodynamics | |||||||
| Heart rate, bpm (n = 77) | 79 ± 16 | 76 ± 14 | 81 ± 17 | 0.11 | 76 ± 14 | 80 ± 17 | 0.36 |
| SBP, mm Hg (n = 73) | 119 ± 23 | 123 ± 26 | 116 ± 20 | 0.20 | 121 ± 26 | 118 ± 22 | 0.61 |
| DBP, mm Hg (n = 73) | 69 ± 11 | 69 ± 12 | 70 ± 11 | 0.85 | 69 ± 13 | 69 ± 11 | 0.97 |
| Mean RA pressure, mm Hg (n = 82) | 14 ± 12 | 14 ± 7 | 13 ± 6 | 0.32 | 13 ± 6 | 14 ± 6 | 0.58 |
| RVSP, mm Hg (n = 83) | 44 ± 14 | 40 ± 12 | 47 ± 15 | 0.01 | 40 ± 10 | 46 ± 16 | 0.03∗ |
| RVEDP, mm Hg (n = 81) | 9 ± 6 | 9 ± 6 | 10 ± 6 | 0.42 | 9 ± 6 | 9 ± 6 | 0.55 |
| SPAP, mm Hg (n = 86) | 45 ± 13 | 40 ± 11 | 48 ± 14 | < 0.01 | 40 ± 10 | 48 ± 15 | 0.01 |
| DPAP, mm Hg (n = 86) | 22 ± 8 | 20 ± 7 | 24 ± 8 | 0.02 | 20 ± 6 | 23 ± 8 | 0.11 |
| MPAP, mm Hg (n = 86) | 30 ± 10 | 27 ± 8 | 33 ± 10 | < 0.01 | 27 ± 7 | 32 ± 10 | 0.03 |
| PCWP, mm Hg (n = 83) | 19 ± 7 | 17 ± 7 | 21 ± 8 | 0.02 | 18 ± 7 | 20 ± 8 | 0.21 |
| PA saturation, % (n = 43) | 61 ± 10 | 63 ± 8 | 59 ± 12 | 0.20 | 62 ± 9 | 61 ± 10 | 0.69 |
| CO, L/min (n = 74) | 4.0 ± 1.4 | 3.9 ± 1.3 | 4.1 ± 1.5 | 0.59 | 4.1 ± 1.1 | 4.0 ± 1.5 | 0.68 |
| CI, L/min/m2 (n = 74) | 2.1 ± 0.6 | 2.1 ± 0.5 | 2.1 ± 0.6 | 0.50 | 2.2 ± 0.5 | 2.0 ± 0.6 | 0.30 |
| TPG, mm Hg (n = 82) | 11 ± 5 | 10 ± 4 | 12 ± 6 | 0.11 | 9 ± 4 | 12 ± 6 | 0.02 |
| DPG, mm Hg (n = 83) | 3 ± 4 | 2 ± 3 | 3 ± 4 | 0.80 | 2 ± 3 | 3 ± 4 | 0.30 |
| PVR, Wood units (n = 72) | 2.5 (1.5-3.9) | 2.2 (1.5-3.9) | 2.6 (1.4-3.9) | 0.48 | 2.0 (1.5-2.9) | 2.7 (1.8-4.2) | 0.07 |
| PAC, mL/mm Hg (n = 67) | 2.3 (1.6-3.6) | 2.5 (1.8-3.7) | 2.1 (1.3-3.0) | 0.07 | 2.6 (2.2-3.5) | 1.9 (1.3-3.6) | 0.05 |
| PA elastance, mm Hg/mL (n = 67) | 0.8 (0.6-1.2) | 0.7 (0.6-0.9) | 0.9 (0.6-1.4) | 0.07 | 0.7 (0.6-0.9) | 0.9 (0.6-1.4) | 0.04 |
bpm, beats per minute; CI, cardiac index; CO, cardiac output; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; DPAP, diastolic pulmonary artery pressure; DPG, diastolic pulmonary gradient; GFR, glomerular filtration rate; MELD, model for end-stage liver disease; MPAP, mean pulmonary artery pressure; PA, pulmonary artery; PAC, pulmonary artery compliance; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance, RA, right atrial; RVEDP, right-ventricular end-diastolic pressure; RVSP, right-ventricular systolic pressure; SBP, systolic blood pressure; SPAP, systolic pulmonary artery pressure; TPG, transpulmonary gradient; TVr, tricuspid valve repair; TVR, tricuspid valve replacement.
Statistically significant P value of < 0.05.